{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiglj5236g72nnz77brpooprhlwzbazamfka7dci4xrvuz57m34kha",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mfshhbs3tb42"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiegjj2nc5htmsga5zhgui6o3ckibqpzwa74gzfre67ifxp7fq6e6i"
    },
    "mimeType": "image/jpeg",
    "size": 103431
  },
  "path": "/news/2026-02-fda-dupixent-allergic-fungal-rhinosinusitis.html",
  "publishedAt": "2026-02-26T18:10:06.000Z",
  "site": "https://medicalxpress.com",
  "tags": [
    "Inflammatory disorders"
  ],
  "textContent": "The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) and a history of sino-nasal surgery.",
  "title": "FDA approves Dupixent for allergic fungal rhinosinusitis"
}